Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors

Por Bisi, John E., Sorrentino, Jessica A., Jordan, Jamie L., Darr, David D., Roberts, Patrick J., Tavares, Francis X., Strum, Jay C.
Publicado no Oncotarget (2017)

Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy

Por Roberts, Patrick J., Bisi, John E., Strum, Jay C., Combest, Austin J., Darr, David B., Usary, Jerry E., Zamboni, William C., Wong, Kwok-Kin, Perou, Charles M., Sharpless, Norman E.
Publicado em 2012

Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion

Por He, Shenghui, Roberts, Patrick J., Sorrentino, Jessica A., Bisi, John E., Storrie-White, Hannah, Tiessen, Renger G., Makhuli, Karenann M., Wargin, William A., Tadema, Henko, van Hoogdalem, Ewoud-Jan, Strum, Jay C., Malik, Rajesh, Sharpless, Norman E.
Publicado no Sci Transl Med (2017)

CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation

Por Deng, Jiehui, Wang, Eric S., Jenkins, Russell W., Li, Shuai, Dries, Ruben, Yates, Kathleen, Chhabra, Sandeep, Huang, Wei, Liu, Hongye, Aref, Amir R., Ivanova, Elena, Paweletz, Cloud P., Bowden, Michaela, Zhou, Chensheng W., Herter-Sprie, Grit S., Sorrentino, Jessica A., Bisi, John E, Lizotte, Patrick H., Merlino, Ashley A., Quinn, Max M., Bufe, Lauren E., Yang, Annan, Zhang, Yanxi, Zhang, Hua, Gao, Peng, Chen, Ting, Cavanaugh, Megan E., Rode, Amanda J., Haines, Eric, Roberts, Patrick J., Strum, Jay C, Richards, William G., Lorch, Jochen H., Parangi, Sareh, Gunda, Viswanath, Boland, Genevieve M., Bueno, Raphael, Palakurthi, Sangeetha, Freeman, Gordon J, Ritz, Jerome, Haining, W. Nicholas, Sharpless, Norman E., Arthanari, Haribabu, Shapiro, Geoffrey I., Barbie, David A., Gray, Nathanael S., Wong, Kwok-Kin
Publicado no Cancer Discov (2017)